Aviragen Therapeutics (AVIR) Tops Q2 EPS by 18c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q2 EPS of ($0.48), $0.18 better than the analyst estimate of ($0.66).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Tesla (TSLA) call put ratio 1.2 calls to 1 put with a focus on 1500 contracts of September 100 puts
• Synchrony partners with OpenAI to integrate AI into shopping